![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260914_SonoThera_Leadership_Tracker-768x512.png\"){kind=tracking}
<\/p>\n<\/p>\n
Company:<\/strong> SonoThera \u00b7 Event Type:<\/strong> Executive Appointment \u00b7 New CMO:<\/strong> Adam J. Shaywitz, M.D., Ph.D. \u00b7 Context:<\/strong> RIPPLE Ultrasound-Mediated Nonviral Genetic Delivery Platform Approaching Clinic \u00b7 Date:<\/strong> September 14, 2026<\/p>\n SonoThera appointed Adam J. Shaywitz, M.D., Ph.D., chief medical officer. He joins after serving as chief medical officer of BridgeBio Gene Therapy and brings experience across AAV gene therapy, rare disease, enzyme replacement and first-in-human development. The appointment adds relevant clinical and regulatory leadership as SonoThera advances its ultrasound-mediated, nonviral genetic-medicine platform toward the clinic. The announcement does not disclose a separate effective date, a predecessor, the specific reason for creating or filling the role, a continuing role elsewhere, or compensation terms.<\/p>\n The appointment was announced on September 14. SonoThera said Shaywitz will help shape translational and clinical development strategy. At BridgeBio Gene Therapy, he led clinical and medical strategy for programs including AAV therapies in congenital adrenal hyperplasia and Canavan disease and contributed to the RMAT designation for BBP-812. Earlier roles included executive medical director at BioMarin and medical director at Amgen. Leadership continuity appears intact: co-founder and chief executive Kenneth Greenberg remains in place, and no departure or board transition was announced.<\/p>\n Bull case:<\/strong> Stage-appropriate capability building. SonoThera’s platform combines ultrasound-mediated delivery with engineered genetic payloads, so moving from preclinical studies into human trials requires integrated protocol design, dose escalation, organ-specific safety monitoring, regulatory interactions and long-term follow-up \u2014 directly relevant to Shaywitz’s prior work.<\/p>\n Bear case:<\/strong> Primarily organizational maturation rather than a near-term clinical catalyst. A CMO hire can precede a lengthy period of translational work; SonoThera did not disclose an IND clearance, trial start, nominated clinical candidate, budget or timeline with the appointment.<\/p>\n SonoThera is developing RIPPLE, an ultrasound-mediated delivery approach, together with PORE payload engineering. The concept uses focused ultrasound and microbubble-mediated sonoporation to transiently increase cellular uptake in selected tissues, potentially enabling local delivery of DNA, RNA, gene-editing or gene-silencing payloads without a viral vector. The company has highlighted Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease among areas of interest. No human efficacy or safety data were disclosed with the appointment.<\/p>\n This is a neutral, moderate-importance leadership signal. Shaywitz’s background is well aligned with the clinical-development problems facing a nonviral genetic-delivery company, but background alone does not establish a strategic pivot, regulatory advantage or near-term clinical readiness.<\/p>\n Importance:<\/strong> 3\/5 \u00b7 Direction:<\/strong> Neutral \u00b7 Confidence:<\/strong> High on facts (moderate on timing; no separate effective date disclosed), Low-moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":" SonoThera appointed Adam J. Shaywitz, M.D., Ph.D., chief medical officer. He joins after serving as chief medical officer of BridgeBio Gene Therapy and brings experience across AAV gene therapy, rare disease, enzyme replacement and…<\/p>\n","protected":false},"author":1,"featured_media":3131,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,196],"tags":[84,83],"class_list":["post-3123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-leadership-tracker","tag-duchenne-muscular-dystrophy","tag-sonothera"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3123"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3123\/revisions"}],"predecessor-version":[{"id":3145,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3123\/revisions\/3145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3131"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
\n Factor<\/th>\n Assessment<\/th>\n<\/tr>\n \n Appointment<\/td>\n Adam J. Shaywitz, M.D., Ph.D. named CMO, effective date not separately disclosed<\/td>\n<\/tr>\n \n Background<\/td>\n CMO at BridgeBio Gene Therapy (AAV programs, RMAT for BBP-812); executive medical director at BioMarin; medical director at Amgen<\/td>\n<\/tr>\n \n Stated Rationale<\/td>\n Shape translational and clinical development strategy as platform moves toward the clinic<\/td>\n<\/tr>\n \n Disclosed Milestones<\/td>\n None; no IND, trial start, or nominated clinical candidate disclosed<\/td>\n<\/tr>\n \n Signal Type<\/td>\n Clinical leadership appointment ahead of first-in-human planning for a nonviral delivery platform<\/td>\n<\/tr>\n<\/table>\n InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n